Keros Therapeutics (KROS)

• Market cap: $216M
• 1 day: -1.44%
• 5 days: -0.81%
• 1 month: -32.35%
• 3 months: -48.64%
• 6 months: -31.07%
• Year to date: -40.88%
• 1 year: -4.2%
• 5 years: -80.8%
• 10 years: -45.42%
• Sector: Healthcare
• Industry: Biotechnology

About: Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Employees: 78